江苏金丝利药业股份有限公司

Jiangsu Jinsili Pharmaceutical is a specialized biopharmaceutical company based in Nanjing, China, with a strong focus on genetic engineering and biotechnology. Founded in 1992, the company is recognized as one of the earliest domestic producers of recombinant human interferon α2b, which remains its flagship product line marketed under the Jinsili brand. Its commercial portfolio includes various delivery formats such as injections, gels, and sprays used primarily for treating viral hepatitis, condyloma acuminatum, and other viral diseases. The company operates state-of-the-art GMP-certified facilities and integrates R&D with large-scale manufacturing and distribution. Jiangsu Jinsili continues to leverage its expertise in cytokines and recombinant proteins to address unmet needs in infectious diseases and oncology.